Antifibrotic constituents of Alnus firma on hepatic stellate cells

Suppression of hepatic stellate cell (HSC) growth and activation have been proposed as therapeutic strategies for the treatment and prevention of liver fibrosis. In the course of screening antifibrotic activity of natural products, the methanolic extract of Alnus firma barks (Betulaceae) showed inhibitory activity of cell proliferation on HSC-T6 cells. A new triterpenoid characterized as lup-20(29) en-2,28-diol-3-yl caffeate (13) was isolated with 12 known diarylheptanoids (1–12) from the barks of A. firma using bioactivity-guided fractionation. Among these compounds, 2 and 13 significantly inhibited the proliferation of HSCs in dose- and time-dependent manners at concentrations from 10 to 100 μM. Taken together, antifibrotic activities of A. firma and its active constituents might suggest the therapeutic potentials against liver fibrosis.

A new triterpenoid characterized as lup-20(29) en-2,28-diol-3-yl caffeate was isolated with 12 known diarylheptanoids from the barks of Alnus firma. Antifibrotic constituents of A. firma on HSCs might suggest the therapeutic potentials against liver fibrosis.Figure optionsDownload as PowerPoint slide